-+ 0.00%
-+ 0.00%
-+ 0.00%

CULLINAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PLANNED REGISTRATIONAL PHASE 2 STUDY OF CLN-049 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Reuters·10/08/2026 11:02:22